Innovation in inflammation.
Xigen SA
Incorporated
14.01.2002Headquarters
LausanneSupport
Sectors
News
16.01.2017
Xigen’s Brimapitide Delivers Positive Phase II Results in Inflammatory Eye Disease (startupticker.ch)